ArticleOphthalmology and therapy2026
Experiences and Perspectives on Diabetic Retinopathy Screening and Treatment in Mexico: A Subanalysis of the Diabetic Retinopathy Barometer Study.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of vision loss worldwide and represent a growing public health concern in Mexico. Despite the availability of effective treatments, including anti-vascular endothelial growth factor (anti-VEGF) therapies, adherence and persistence remain suboptimal, compromising outcomes. This study, part of the international DR Barometer project, examined the perspectives of patients, healthcare providers, and clinic staff to better understand challenges and opportunities in DR/DME care delivery in Mexico.
methodsA cross-sectional, survey-based study was conducted across five high-volume ophthalmology clinics in Mexico. Standardized, paper-based questionnaires were completed anonymously by patients with DR or DME, healthcare providers, and clinic staff. Data were collected between October and November 2023, scanned, and analyzed descriptively.
resultsA total of 1151 participants were included: 558 patients with DME, 265 patients with DR, 122 providers, and 206 clinic staff. Key barriers to adherence included financial burden of treatment (reported by 67.4% of patients with DME; emphasized by 97.5% of providers), logistical difficulties such as travel and long waiting times, and emotional concerns about being a burden to family (71.5% of patients with DME; 61.1% of patients with DR). Nonadherent patients were more likely to prioritize competing health issues and report limited support from care teams. While most patients stated that eye treatment was a priority (87-91%), only 61% of providers believed this to be true. Opportunities highlighted across stakeholders included proactive provider-patient communication, continuity of care with the same clinical team, appointment reminders, and financial assistance. Clinic staff emphasized the need for improved educational materials and better coordination of diabetes and eye care services.
conclusionsThis study reveals substantial challenges to adherence in DR/DME management in participating Mexican referral centers, rooted in financial, logistical, and psychosocial factors. Strengthening communication, expanding financial support, and integrating coordinated, patient-centered care strategies could improve long-term treatment engagement and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.